



ABN 53 075 582 740

ASX ANNOUNCEMENT
27 September 2013

BIONOMICS TO PRESENT BNC375 AT COGNITO NEUROSCIENCE MEETING

Bionomics Limited (ASX: BNO, ADR: BMICY) Vice-President of Neuroscience Research Dr Sue O'Connor will today present Bionomics' BNC375 drug candidate for Alzheimer's disease and other cognitive disorders at the annual COGNITO meeting in Copenhagen, Denmark.

Dr O'Connor's presentation, *BNC375, a positive allosteric modulator of the $\alpha 7$ nicotinic acetylcholine receptor for treatment of cognitive impairment*, will discuss the Bionomics drug candidate developed as part of the Company's $\alpha 7$ program.

As well as Alzheimer's disease, BNC375 has the potential to be effective in a number of other multi-billion dollar markets including schizophrenia, Parkinson's disease and ADHD.

There is a large body of evidence implicating the $\alpha 7$ nAChR in the pathophysiology of several neurodegenerative and neuropsychiatric diseases. Modulation of this receptor enhances cognitive processes, for example attention, which is compromised in these disorders.

BNC375 has in vivo memory enhancing properties that have been demonstrated in animal models of cognitive impairment. Both episodic memory and working memory were found to be improved while equivalent performance was found when compared to Donepezil, a Pfizer product marketed as Aricept which is used to treat cognitive and behavioural effects of mild to moderate Alzheimer's disease.

BNC375 has a 100-fold therapeutic dose range and has demonstrated a wide safety window in preclinical studies conducted to date.

COGNITO is a five-year translational neuroscience program funded by the Strategic Research Council of Denmark. The program brings together Danish and international scientists combining basic neuroscience, industrial drug-discovery, molecular brain imaging, biomarker discovery and clinical research in the aim of defining novel treatments of cognitive dysfunction.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group
Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited

Bionomics (ASX: BNO) is an Australian based international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and autoimmune disorders, several of which are in or approaching clinical development stage. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.

BNC105, which is undergoing Phase II clinical development for the treatment in a range of solid tumour types, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. BNC105 offers blockbuster potential if successfully developed. A clinical program is also underway for the treatment of anxiety disorders and depression based on IW-2143(BNC210), a novel compound which stimulates neurite outgrowth. IW-2143 is partnered with Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX®, a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, IW-2143 (BNC210), BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deals with Ironwood Pharmaceuticals and Merck, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Ironwood's decisions to continue or not continue development of IW-2143, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.